A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)

INTERVENTION: Experimental group:Oral administration of 5 tablets of 1mg Azvudine tablets daily;Control group:According to the "Pneumonia Diagnosis and Treatment Plan for New Coronavirus Infection (Trial Version 5)" issued by National Health Commission of People's Republic of China, the subjects were given corresponding treatment.; CONDITION: Novel Coronavirus Pneumonia (COVID‐19) PRIMARY OUTCOME: time and rate of temperature return to normal;;time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.);time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms;time and rate of pulmonary imaging improvement;time and rate of change to negative COVID‐19 nucleic acid test;time and rate of improvement of oxygenation measurement;improvement time and rate of CD4 count;rate of mild/modorate type to severe type, rate of severe type to critical type;length of hospitalization;mortality; INCLUSION CRITERIA: (1) aged >=18 years old; (2) real‐time fluorescence rt‐pcr of respiratory or blood samples presents the positive nucleic acid of COVID‐19, or the viral gene sequencing of respiratory or blood samples was highly homologous with the known COVID‐19. (3) patients diagnosed with novel coronavirus meet the diagnostic criteria of the latest clinical guidelines for novel coronavirus issued by the world health organization (WHO) on January 28, 2020 and the diagnostic criteria of the pneumonia diagnosis and treatment program for novel coronavirus infection (trial version 5) issued by National Health commission of the People's Republic of China.